BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 17101674)

  • 21. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.
    Feng JY; Cheng G; Perry J; Barauskas O; Xu Y; Fenaux M; Eng S; Tirunagari N; Peng B; Yu M; Tian Y; Lee YJ; Stepan G; Lagpacan LL; Jin D; Hung M; Ku KS; Han B; Kitrinos K; Perron M; Birkus G; Wong KA; Zhong W; Kim CU; Carey A; Cho A; Ray AS
    Antimicrob Agents Chemother; 2014; 58(4):1930-42. PubMed ID: 24419349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase.
    Wu JZ; Yao N; Walker M; Hong Z
    Mini Rev Med Chem; 2005 Dec; 5(12):1103-12. PubMed ID: 16375756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 2'-deoxy-2'-fluoro-2'-C-methyl uridine cyclopentyl carbocyclic analog and its phosphoramidate prodrug as inhibitors of HCV NS5B polymerase.
    Liu J; Du J; Wang P; Nagarathnam D; Espiritu CL; Bao H; Murakami E; Furman PA; Sofia MJ
    Nucleosides Nucleotides Nucleic Acids; 2012 Apr; 31(4):277-85. PubMed ID: 22444190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of interactions between hepatitis C virus NS5B polymerase, annexin A2 and RNA - effects on NS5B catalysis and allosteric inhibition.
    Solbak SMØ; Abdurakhmanov E; Vedeler A; Danielson UH
    Virol J; 2017 Dec; 14(1):236. PubMed ID: 29228983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system.
    Bassit L; Grier J; Bennett M; Schinazi RF
    Antivir Chem Chemother; 2008; 19(1):25-31. PubMed ID: 18610555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of aurintricarboxylic acid as a potent hepatitis C virus replicase inhibitor.
    Chen Y; Bopda-Waffo A; Basu A; Krishnan R; Silberstein E; Taylor DR; Talele TT; Arora P; Kaushik-Basu N
    Antivir Chem Chemother; 2009 Sep; 20(1):19-36. PubMed ID: 19794229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nucleoside analog inhibitors of hepatitis C virus replication.
    Carroll SS; Olsen DB
    Infect Disord Drug Targets; 2006 Mar; 6(1):17-29. PubMed ID: 16787301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
    Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
    Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094.
    Ehteshami M; Tao S; Ozturk T; Zhou L; Cho JH; Zhang H; Amiralaei S; Shelton JR; Lu X; Khalil A; Domaoal RA; Stanton RA; Suesserman JE; Lin B; Lee SS; Amblard F; Whitaker T; Coats SJ; Schinazi RF
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4659-69. PubMed ID: 27216050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to excision determines efficiency of hepatitis C virus RNA-dependent RNA polymerase inhibition by nucleotide analogs.
    Villalba B; Li J; Johnson KA
    J Biol Chem; 2020 Jul; 295(30):10112-10124. PubMed ID: 32457046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canonical 3'-deoxyribonucleotides as a chain terminator for HCV NS5B RNA-dependent RNA polymerase.
    Shim J; Larson G; Lai V; Naim S; Wu JZ
    Antiviral Res; 2003 May; 58(3):243-51. PubMed ID: 12767472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2'-deoxy-2'-fluorocytidine.
    Stuyver LJ; McBrayer TR; Whitaker T; Tharnish PM; Ramesh M; Lostia S; Cartee L; Shi J; Hobbs A; Schinazi RF; Watanabe KA; Otto MJ
    Antimicrob Agents Chemother; 2004 Feb; 48(2):651-4. PubMed ID: 14742230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphorylation of hepatitis C virus RNA polymerases ser29 and ser42 by protein kinase C-related kinase 2 regulates viral RNA replication.
    Han SH; Kim SJ; Kim EJ; Kim TE; Moon JS; Kim GW; Lee SH; Cho K; Yoo JS; Son WS; Rhee JK; Han SH; Oh JW
    J Virol; 2014 Oct; 88(19):11240-52. PubMed ID: 25031343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
    Sofia MJ; Bao D; Chang W; Du J; Nagarathnam D; Rachakonda S; Reddy PG; Ross BS; Wang P; Zhang HR; Bansal S; Espiritu C; Keilman M; Lam AM; Steuer HM; Niu C; Otto MJ; Furman PA
    J Med Chem; 2010 Oct; 53(19):7202-18. PubMed ID: 20845908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation.
    Zhen L; Dai L; Wen X; Yao L; Jin X; Yang XW; Zhao W; Yu SQ; Yuan H; Wang G; Sun H
    J Med Chem; 2017 Jul; 60(14):6077-6088. PubMed ID: 28650160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ligand-induced changes in hepatitis C virus NS5B polymerase structure.
    Rigat K; Wang Y; Hudyma TW; Ding M; Zheng X; Gentles RG; Beno BR; Gao M; Roberts SB
    Antiviral Res; 2010 Nov; 88(2):197-206. PubMed ID: 20813137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cell-based assay for RNA synthesis by the HCV polymerase reveals new insights on mechanism of polymerase inhibitors and modulation by NS5A.
    Ranjith-Kumar CT; Wen Y; Baxter N; Bhardwaj K; Cheng Kao C
    PLoS One; 2011; 6(7):e22575. PubMed ID: 21799903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current perspective of HCV NS5B inhibitors: a review.
    Patil VM; Gupta SP; Samanta S; Masand N
    Curr Med Chem; 2011; 18(36):5564-97. PubMed ID: 22172066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.
    Ludmerer SW; Graham DJ; Boots E; Murray EM; Simcoe A; Markel EJ; Grobler JA; Flores OA; Olsen DB; Hazuda DJ; LaFemina RL
    Antimicrob Agents Chemother; 2005 May; 49(5):2059-69. PubMed ID: 15855532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
    McCown MF; Rajyaguru S; Le Pogam S; Ali S; Jiang WR; Kang H; Symons J; Cammack N; Najera I
    Antimicrob Agents Chemother; 2008 May; 52(5):1604-12. PubMed ID: 18285474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.